Results of one-year follow-up examinations after intravitreal bevacizumab administration for chronic central serous chorioretinopathy.

Abstract

BACKGROUND:

our purpose was to report the results of 1-year follow-up examinations after intravitreal bevacizumab injection for the treatment of chronic central serous chorioretinopathy (CSC).

METHODS:

five eyes in 5 patients with chronic CSC were intravitreally injected with 1.25 mg/0.05 ml of bevacizumab. The need for retreatment was evaluated if spectral-domain optical coherence tomography showed the presence of subretinal fluid at the time of a 1-month follow-up examination. Best-corrected visual acuity and central foveal thickness were compared between baseline and 1 year after the first injection.

RESULTS:

the mean logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity improved from 0.23 ± 0.46 to 0.17 ± 0.47 and the mean central foveal thickness significantly decreased from 323 ± 98 microm to 171 ± 63 microm (p < 0.05).

CONCLUSION:

The intravitreal injection of bevacizumab is well tolerated in maintaining vision and reducing serous retinal detachment in patients with chronic CSC, as evaluated at a 1-year follow-up examination.

• Authors: Maiko Inoue, Kazuaki Kadonosono, Yoichiro Watanabe, Satoshi Kobayashi, Shin Yamane, Akira Arakawa
• Journal: Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde (Ophthalmologica) Vol. 225 Issue 1 Pg. 37-40 ( 2011) ISSN: 1423-0267 [Electronic] Switzerland
• PMID: 20693820 (Publication Type: Journal Article)
• Copyright: 2010 S. Karger AG, Basel.

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• VEGFA protein, human
• Vascular Endothelial Growth Factor A
• Bevacizumab

Topics

• Adult
• Angiogenesis Inhibitors (administration & dosage)
• Antibodies, Monoclonal (administration & dosage)
• Antibodies, Monoclonal, Humanized
• Bevacizumab
• Central Serous Chorioretinopathy (diagnosis, drug therapy, physiopathology)
• Chronic Disease
• Female
• Fluorescein Angiography
• Follow-Up Studies
• Humans
• Intravitreal Injections
• Male
• Middle Aged
• Prospective Studies
• Retina (pathology)
• Retinal Detachment (prevention & control)
• Retreatment
• Tomography, Optical Coherence
• Treatment Outcome
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)
• Visual Acuity (physiology)